Zhengda Gene and UnknownJUN Announce Strategic Collaboration to Advance Gut Microbiome Therapeutics and File Joint IPO Prospectus

Stock trading depends onGolden Qilin Analyst Report, authoritative, professional, timely, comprehensive, help you explore potential thematic opportunities!

(Source: Elephant News)

On May 14, Zhengda Gene, a biomedical research platform under Zhengzhou University, officially reached an in-depth strategic cooperation with Xbiome, a leading intestinal microbiota technology enterprise in China. An awarding ceremony was held in the meeting room of Zhengda Gene. Hu Hongtao, Director of the Science and Technology Cooperation Department of Zhengzhou Municipal Science and Technology Bureau, as well as senior executives and representatives of the scientific research teams from both sides, attended the event to witness this important milestone in cross-regional biomedical cooperation.

During the event, Hu Hongtao, Director of the Science and Technology Cooperation Department of Zhengzhou Municipal Science and Technology Bureau, delivered a speech as a government guest. He highly praised the innovative value of this cross-disciplinary collaboration between Zhengda Gene and Xbiome, pointing out that this is not only a partnership between enterprises but also an exemplary model of deep integration of "industry-university-research-application." Hu Hongtao stated that the Zhengzhou Municipal Science and Technology Bureau will continue to optimize technology investment promotion and policy environment, strongly supporting such cross-regional and interdisciplinary industrial collaboration projects to inject new momentum into the high-quality development of Zhengzhou's biomedicine industry.

Subsequently, Lei Zhiliang, Chairman of Zhengda Gene, stated that Zhengda Gene is a new biopharmaceutical enterprise initiated by Zhengzhou University, gathering the strengths of top scientists such as Professor Shutao Zhang's team and Dr. Dan Wei's team. The company focuses on gene technology and cell therapy and has established a dual pipeline layout for cell therapy IgA nephritis drugs (Clinical IIT stage) and malignant solid tumors. Lei Zhiliang emphasized that this cooperation is a crucial step in Zhengda Gene's dual-driven strategy of R&D + health services, which will leverage Xbiome's microbiome technology to complete a full life cycle health management closed loop.

Xbiome General Manager Hao Yi stated in his speech that Xbiome, as a leading microbiome research and industrial transformation platform in China, has established an FMT (fecal microbiota transplantation) production system that meets FDA standards and owns the first FMT drug pipeline in Asia to receive FDA clinical approval. He pointed out that Zhengzhou is the medical hub of central China. This collaboration with Zhengda Gene aims to deeply integrate Xbiome's "AI+BT" technology platform with Zhengda Gene’s R&D laboratories, medical centers, and market resources to jointly create a central China highland for gut microbiome diagnosis and treatment.

Immediately following, Dr. Wei Dan from Zhengzhou University, Director Zhang Bowen, and General Manager Hao Yi from Xbiome respectively provided in-depth explanations on their technical layouts, research progress, and future plans.

Under the spotlight of the entire audience, both parties officially signed the strategic cooperation agreement and exchanged plaques as strategic partner units, simultaneously launching the "ZZU Genes & Xbiome AI+BT Joint Microbiology Lab".

After the signing ceremony, Shi Like, General Manager of Zhengda Gene Quanwei Life, delivered a summary speech. Ms. Shi stated that Quanwei Life Clinic is a high-end health management institution under Zhengda Gene, focusing on precision medicine and full-cycle life health services. Backed by strong scientific research capabilities, it provides personalized health solutions covering the entire process of testing, evaluation, intervention, and management, with the aim of improving quality of life and safeguarding a healthy future. She expressed that both parties would take this as an opportunity to fully leverage Zhengda Gene's advantages as a local brand and its own scientific research strengths, actively integrate resources, and solidify Zhengda Gene’s position as a strategic stronghold for Xbiome in the Henan market. The collaboration will also expand the commercial landscape and enhance Xbiome's influence in the Henan market.

The afternoon intestinal microbiota science popularization salon specially invited Director Zheng Min, a senior expert, to give a lecture. With over two decades of clinical experience in public tertiary hospitals, Director Zheng delivered a talk titled "Intestinal Age Determines Lifespan – Decoding the Microbiome Secrets Behind Longevity." From the rigorous perspective of clinical medicine, she provided an in-depth analysis of the core role of gut microbiota as the human body's second genome. Her presentation not only greatly enhanced the academic value of this salon but also enabled the audience to deeply understand the crucial role of intestinal microbiota in precision health management, laying a solid theoretical and practical foundation for the subsequent product interpretation and market outlook sessions.

Subsequently, Director Liu Xuan, Chief Health Expert of Zhengda Gene, combined with the academic sharing of the guests, further shared real customer case feedback on oral probiotics, testing, and intervention, using practical results to validate technological value; Teacher Zhao Mingyang, Chief Science Popularization Expert of Zhengda Gene, provided a detailed explanation of the relevant service processes and product systems.

This deep collaboration between Zhengda Gene and Xbiome not only represents a two-way empowerment between an academic brand from a university and a leading industry brand, significantly enhancing the industry authority and public recognition of both parties, but also marks Xbiome's official expansion into Henan Province, establishing a strategic foothold by leveraging Zhengda Gene's local resources.

Both parties will engage in deep collaboration, relying on joint scientific research efforts, focusing on major health challenges such as cancer and metabolic diseases, accelerating the transition of research achievements from the laboratory to practical applications, contributing core strength to enhance regional medical technology levels and support the construction of Healthy China, and jointly writing a new chapter in China's precision health industry.

Review: Wang Tingjie